Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Higher maternal age linked to increased risk of adverse pregnancy outcomes

25 Feb 2018

The risk of unfavourable pregnancy outcomes, such as chromosomal abnormalities, miscarriage and birth before 34 weeks of gestation, appears to be heightened in women aged >40 years than in those who are younger, according to a study from Denmark.

Researchers analysed data from a nationwide cohort of 369,516 singleton pregnancies followed from 11 to 14 weeks of gestation to delivery or termination of pregnancy. Pregnant women aged 35 years were divided into two advanced maternal age groups (35–39 years and 40 years) and compared with pregnant women aged 20–34 years. Adverse pregnancy outcomes investigated were chromosomal abnormalities, congenital malformations, miscarriage, stillbirth and birth before 34 weeks of gestation.

At least one of the selected adverse pregnancy outcomes occurred in 10.82 percent of pregnant women aged 40 years vs 5.46 percent of pregnant women aged 20–34 years (odds ratio [OR], 2.02; 99.8 percent CI, 1.78–2.29).

Compared with those who were younger, older pregnant women had a higher risk of chromosomal abnormalities (3.83 percent vs 0.56 percent; OR, 7.44; 5.93–9.34), miscarriage (1.68 percent vs 0.42 percent; OR, 3.10; 2.19–4.38) and birth before 34 weeks of gestation (2.01 percent vs 1.21 percent; OR, 1.66; 1.23–2.24). No such increase was observed in the risk of congenital malformations and stillbirth.

The risk prediction chart showed that advanced maternal age, use of assisted reproductive technology, nulliparous pregnancy, smoking during pregnancy and obesity all increased the absolute predictive risk of an adverse pregnancy outcome.

Findings of the present study indicate that while several factors increase the risk of adverse pregnancy outcomes, advanced maternal age drives a high proportion of the total risk score. This highlights the importance of closely monitoring pregnancies in women aged >40 years.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.